An organic compound represented by the formula [1]:

##STR00001##

R.sub.1 to R.sub.19 are independently selected from the group consisting of a hydrogen atom, a deuterium atom, a halogen atom, and a substituent, and R.sub.9 and R.sub.19 are optionally bonded together. When R.sub.9 and R.sub.19 are bonded together, the bonding is selected from the group consisting of direct bonding, bonding via an oxygen atom or a sulfur atom, and bonding via CR.sub.20R.sub.21. R.sub.20 and R.sub.21 independently have the same meaning as R.sub.1 to R.sub.19. X.sub.1 and X.sub.2 independently denote an oxygen atom, a sulfur atom, CR.sub.20R.sub.21, or a single bond. Ar denotes an aromatic hydrocarbon group or a heterocyclic group, n denotes an integer in the range of 0 to 2, and m denotes an integer in the range of 1 to 4. When n is 0, any one of R.sub.1 to R.sub.8 is directly bonded to any one of R.sub.9 to R.sub.19.

An organic compound represented by the formula [1]:

##STR00001##

R.sub.1 to R.sub.19 are independently selected from the group consisting of a hydrogen atom, a deuterium atom, a halogen atom, and a substituent, and R.sub.9 and R.sub.19 are optionally bonded together. When R.sub.9 and R.sub.19 are bonded together, the bonding is selected from the group consisting of direct bonding, bonding via an oxygen atom or a sulfur atom, and bonding via CR.sub.20R.sub.21. R.sub.20 and R.sub.21 independently have the same meaning as R.sub.1 to R.sub.19. X.sub.1 and X.sub.2 independently denote an oxygen atom, a sulfur atom, CR.sub.20R.sub.21, or a single bond. Ar denotes an aromatic hydrocarbon group or a heterocyclic group, n denotes an integer in the range of 0 to 2, and m denotes an integer in the range of 1 to 4. When n is 0, any one of R.sub.1 to R.sub.8 is directly bonded to any one of R.sub.9 to R.sub.19.

The present disclosure relates generally to certain compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions disclosed herein may be used for the treatment or prevention of a Retroviridae viral infection, including an infection caused by the HIV virus.

The present invention relates to compounds of the formula (1), (17) 18) or (20) and to the use thereof in electronic devices, and to electronic devices which contain these compounds. The invention furthermore relates to the preparation of the compounds of the formula (1), (17) 18) or (20) and to formulations contains one or more compounds of the formula (1), (17) 18) or (20).

The present invention relates to compounds of the formula (1), (17) 18) or (20) and to the use thereof in electronic devices, and to electronic devices which contain these compounds. The invention furthermore relates to the preparation of the compounds of the formula (1), (17) 18) or (20) and to formulations contains one or more compounds of the formula (1), (17) 18) or (20).

A condensed cyclic compound is represented by Formula 1 below: ##STR00001##
wherein X.sub.3 is a carbon atom that is one of X.sub.7 and X.sub.8 in Formula A below, X4 is a carbon atom that is the other of X.sub.7 and X.sub.8 in Formula A, or ii) X.sub.5 is a carbon atom that is one of X.sub.7 and X.sub.8 in Formula A, X.sub.6 is a carbon atom that is the other of X.sub.7 and X.sub.8 in Formula A, ##STR00002##

A condensed cyclic compound is represented by Formula 1 below: ##STR00001##
wherein X.sub.3 is a carbon atom that is one of X.sub.7 and X.sub.8 in Formula A below, X4 is a carbon atom that is the other of X.sub.7 and X.sub.8 in Formula A, or ii) X.sub.5 is a carbon atom that is one of X.sub.7 and X.sub.8 in Formula A, X.sub.6 is a carbon atom that is the other of X.sub.7 and X.sub.8 in Formula A, ##STR00002##

An example embodiment relates to an organic semiconductor compound, represented by Chemical Formula 1 herein, which may be polymerized and used in transistors and electronic devices. The organic semiconductor compound includes a base structure of four fused benzene rings with functional groups R.sup.1 to R.sup.3 connected to a first benzene ring and with functional groups R.sup.4 to R.sup.6 connected to a second benzene ring. The base structure's third and fourth benzene rings are connected to X.sup.1, X.sup.2 and X.sup.3, X.sup.4 respectfully. At least one of X.sup.1 and X.sup.2 is a sulfur atom. At least one of X.sup.3 and X.sup.4 is a sulfur atom. The base structure further includes functional groups R.sup.7 and R.sup.8.

An example embodiment relates to an organic semiconductor compound, represented by Chemical Formula 1 herein, which may be polymerized and used in transistors and electronic devices. The organic semiconductor compound includes a base structure of four fused benzene rings with functional groups R.sup.1 to R.sup.3 connected to a first benzene ring and with functional groups R.sup.4 to R.sup.6 connected to a second benzene ring. The base structure's third and fourth benzene rings are connected to X.sup.1, X.sup.2 and X.sup.3, X.sup.4 respectfully. At least one of X.sup.1 and X.sup.2 is a sulfur atom. At least one of X.sup.3 and X.sup.4 is a sulfur atom. The base structure further includes functional groups R.sup.7 and R.sup.8.

The present invention concerns compounds of formula I or pharmaceutically acceptable salts thereof, which inhibit HIF prolyl hydroxylase, their use for enhancing endogenous production of erythropoietin, and for treating conditions associated with reduced endogenous production of erythropoietin such as anemia and like conditions, as well as pharmaceutical compositions comprising such a compound and a pharmaceutical carrier.

##STR00001##